Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$47.86 - $75.05 $382 - $600
8 Added 22.86%
43 $2,000
Q1 2024

May 07, 2024

BUY
$63.75 - $108.06 $2,231 - $3,782
35 New
35 $2,000
Q3 2022

Nov 14, 2022

SELL
$38.54 - $54.52 $231 - $327
-6 Reduced 2.23%
263 $13,000
Q2 2022

Aug 08, 2022

BUY
$33.93 - $48.92 $2,069 - $2,984
61 Added 29.33%
269 $11,000
Q1 2022

May 10, 2022

SELL
$29.74 - $46.0 $178 - $276
-6 Reduced 2.8%
208 $8,000
Q4 2021

Feb 11, 2022

BUY
$34.35 - $46.38 $171 - $231
5 Added 2.39%
214 $10,000
Q3 2021

Nov 08, 2021

BUY
$18.54 - $35.74 $315 - $607
17 Added 8.85%
209 $7,000
Q2 2021

Aug 09, 2021

BUY
$19.79 - $26.99 $1,919 - $2,618
97 Added 102.11%
192 $4,000
Q4 2020

Feb 09, 2021

BUY
$15.26 - $28.61 $198 - $371
13 Added 15.85%
95 $2,000
Q2 2020

Aug 11, 2020

SELL
$11.15 - $24.64 $8,172 - $18,061
-733 Reduced 89.94%
82 $2,000
Q1 2020

May 15, 2020

BUY
$8.75 - $16.3 $7,131 - $13,284
815 New
815 $9,000
Q4 2019

Feb 13, 2020

SELL
$7.95 - $11.84 $21,083 - $31,399
-2,652 Closed
0 $0
Q3 2019

Oct 17, 2019

SELL
$10.82 - $14.25 $79,440 - $104,623
-7,342 Reduced 73.46%
2,652 $31,000
Q2 2019

Aug 05, 2019

BUY
$7.95 - $11.25 $63,687 - $90,123
8,011 Added 403.98%
9,994 $112,000
Q1 2019

Apr 16, 2019

BUY
$5.95 - $10.19 $8,151 - $13,960
1,370 Added 223.49%
1,983 $16,000
Q4 2018

Jan 17, 2019

SELL
$5.91 - $9.29 $1,997 - $3,140
-338 Reduced 35.54%
613 $4,000
Q3 2018

Nov 02, 2018

BUY
$6.4 - $9.85 $6,086 - $9,367
951 New
951 $0
Q1 2018

May 03, 2018

SELL
$7.2 - $10.05 $3,448 - $4,813
-479 Closed
0 $0
Q4 2017

Feb 02, 2018

BUY
$7.25 - $15.65 $384 - $829
53 Added 12.44%
479 $4,000
Q3 2017

Oct 20, 2017

BUY
$12.0 - $15.0 $5,112 - $6,390
426
426 $6,000

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.61B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.